Indian Stock Market

NSR Partner gets 30% stake in Nectar Lifesciences .
Deal values Nectar pharma at Rs.35 per share .
NSR is investing close to 250 crores for this stake .

CIPLA is now India’s No:1 Pharma Company.
Drug company Cipla maintained its top position in the domestic market for the 12 months ended December, 2009, with a market share of 5.38 per cent — up 18 per cent over the year and ahead of Ranbaxy Laboratories and GlaxoSmithKline (GSK).
The total domestic drug market is valued at [...]

CIPLA to supply generics for GSK , TEVA

Orchid chemicals loses its GEM to Hospira.

SRL RANBAXY  | Super Religare Labs ( laboratories ) is planning to launch an IPO ( Initial Public Offering ) this fiscal .
SRL Ranbaxy is owned by Malvinder Singh and Shivinder Singh, the former promoters of Ranbaxy.
SRL Ranbaxy runs diagnostic labs all over the country. The company plans to raise Rs. 200 Crores through IPO.
Company [...]

Glenmark Generics ipo is set to open a new sector ” generics” . Few other companies may follow glenmark generics.
Company plans to raise Rs.500 crores . 10-20 % will be offloaded.
IPO Price range could be Rs.350-450
This is a very good move by the company which can unlock value for investors.

Biocon and Amylin Pharmaceuticals have entered into a partnership.
Biocon has gained on partnership with Amylin Pharmaceuticals for global development and commercialization agreement for a Novel Peptide Hybrid.
BSE | NSE
Price

Also Read

Related Stories
News Now
- Sensex extends losses
- DLF tops combined value chart
- Markets rebound
- Sensex up 60pts [...]

Novartis AG made an open offer to acquire an additional stake of 39% in its Indian subsidiary for a total value of up to Rs 440 crore

The MHRA approval will not only cover product filings for the UK but will also apply to product filings for the entire European Union

Strides Arcolab has terminated a licence and supply pact with US based KV Pharmaceutical Company.

Aurobindo Pharma said it has received US FDA approval for Lopinavir/Ritonavir tablets used in the treatment of HIV infections

Roche Holding AG has struck a deal with Genentech Inc to acquire all outstanding shares in the US biotech group for $46.8 billion

Schering-Plough shareholders will receive 0.5767 shares of Merck and $10.50 in cash

Last week, Microsoft had kicked-off an IT initiative for the pharma cluster in the state

Switzerland’s Roche said on Thursday it has agreed to buy all the remaining shares in Genentech for $46.8 billion in a takeover described as the largest in Swiss corporate history.